Study of GS-0415 and How It Works in People With HIV
A First-in-Human Phase 1b, Single-Blind, Placebo-controlled Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate Safety and Pharmacokinetics of GS-0415 in People With HIV-1 Who Are Virologically Suppressed on Antiretroviral Treatment
The goals of this clinical study are to learn more about the study drug GS-0415, safety, tolerability, and pharmacokinetics (PK) of single ascending doses (SAD) and multiple ascending doses (MAD) of subcutaneous (SC) and intravenous (IV) GS-0415 in people with HIV-1 (PWH) on antiretroviral treatment.
The primary objectives of this study are to evaluate the safety and tolerability of escalating, single and multiple subcutaneous (SC) and intravenous (IV) doses of GS-0415, administered in PWH who are virologically suppressed on antiretroviral therapy (ART) and to evaluate the pharmacokinetics (PK) of GS-0415.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: Gilead Clinical Study Information Center
- Telefonnummer: 1-833-445-3230 (GILEAD-0)
- E-post: GileadClinicalTrials@gilead.com
Studiesteder
-
-
California
-
Los Angeles, California, Forente stater, 90027
- Rekruttering
- Kaiser Permanente Los Angeles Medical Center
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forente stater, 20007
- Rekruttering
- Georgetown University Medical Center
-
-
Florida
-
Miami Lakes, Florida, Forente stater, 33016
- Rekruttering
- Floridian Clinical Research, LLC
-
West Palm Beach, Florida, Forente stater, 33407
- Rekruttering
- Triple O Research Institute, P.A.
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30308
- Rekruttering
- Emory University Hospital Midtown Infectious Disease Clinic
-
Columbus, Georgia, Forente stater, 31904
- Rekruttering
- Centricity Research CPU - Georgia
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46202
- Rekruttering
- Indiana CTSI Clinical Research Center
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02115
- Rekruttering
- Brigham and Women's Hospital
-
Boston, Massachusetts, Forente stater, 02118
- Rekruttering
- Boston Medical Center
-
-
Nevada
-
Las Vegas, Nevada, Forente stater, 89113
- Rekruttering
- PPD Development, LP
-
-
New Jersey
-
Newark, New Jersey, Forente stater, 07102
- Har ikke rekruttert ennå
- St. Michaels Medical Center
-
-
New York
-
The Bronx, New York, Forente stater, 10461
- Rekruttering
- Jacobi Medical Center
-
-
North Carolina
-
Durham, North Carolina, Forente stater, 27710
- Rekruttering
- Duke Early Phase Clinical Research Unit
-
Winston-Salem, North Carolina, Forente stater, 27157
- Rekruttering
- Wake Forest University Health Sciences
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45267
- Rekruttering
- University of Cincinnati College of Medicine
-
Columbus, Ohio, Forente stater, 43210
- Rekruttering
- The Ohio State University Medical Center Infectious Diseases Clinic
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Key Inclusion Criteria:
- Age ≥ 18 years and age ≤ 65 years at screening
- On stable antiretroviral (ARV) treatment for ≥ 12 consecutive months prior to screening, throughout the duration of study treatment and follow-up
- The following ARV agents are not allowed as part of the current ART regimen: entry inhibitors (maraviroc, enfuvirtide, ibalizumab, or fostemsavir)
- Plasma HIV-1 RNA < 50 copies/mL for ≥ 12 months before and at screening with at least 2 documented HIV-1 RNA <50 copies/mL within the last 12 months.
- Clusters of differentiation 4 (CD4) count ≥ 350 cells/μL
- Weight ≥ 50 kg and ≤ 110 kg at screening and Day 1
- Body mass index (BMI) ≥ 18.5 kg/m2 and ≤ 35 kg/m2 at screening and Day 1
Key Exclusion Criteria:
-
Documented history of pre-ART CD4 nadir < 100 cells/μL. Unknown pre-ART CD4 nadir is acceptable
-
Known to have initiated ART within 6 months of HIV infection. Unknown time between infection and ART initiation is acceptable
-
Females who are pregnant or breastfeeding or who may wish to become pregnant during the study or within 42 days after last study drug administration
-
Have chronic hepatitis B virus (HBV) as determined by either:
- Positive HBV surface antigen, regardless of HBV core antibody status, at the Screening visit
- Positive HBV core antibody and negative HBV surface antibody, regardless of HBV surface antigen status, at the Screening visit
-
Have active hepatitis C virus (HCV) infection:
1.) Positive anti-HCV antibody and negative HCV polymerase chain reaction (PCR) results are acceptable
-
Have a history of any of the following:
2.) Significant serious skin disease, such as but not limited to rash, food allergy, eczema, psoriasis, or urticaria as assessed by the investigator
3.) Significant drug sensitivity or drug allergy ('but not limited to anaphylaxis or drug-induced liver injury) as assessed by the investigator
4.) Known hypersensitivity to the study drugs, their metabolites, or to formulation excipients
5.) Previous or current history of bleeding disorder, platelet disorder including unexplained acute or chronic thrombocytopenia
6.) Autoimmune diseases including Type 1 diabetes mellitus
7.) Serious or active medical or psychiatric illness that would interfere with participant treatment, assessment, or compliance with the protocol.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Group A Single Ascending Dose (SAD): GS-0415
Participants will receive single escalating doses of GS-0415 via subcutaneous (SC) or intravenously (IV) on Day 1. |
Administered SC or IV |
|
Eksperimentell: Group A SAD: Placebo
Participants will receive placebo to match the single escalating doses of GS-0415 via SC or IV on Day 1. |
Administered SC or IV |
|
Eksperimentell: Group B SAD: GS-0415
Participants will receive single escalating doses of GS-0415 via SC or IV on Day 1. |
Administered SC or IV |
|
Eksperimentell: Group B SAD: Placebo
Participants will receive placebo to match the single escalating doses of GS-0415 via SC or IV on Day 1. |
Administered SC or IV |
|
Eksperimentell: Group C Multiple Ascending Dose (MAD): GS-0415
Participants will receive escalating doses of GS-0415 via SC or IV at five different timepoints up to Date 57. |
Administered SC or IV |
|
Eksperimentell: Group C MAD: Placebo
Participants will receive placebo to match escalating doses of GS-0415 via SC or IV at five different timepoints up to Day 57. |
Administered SC or IV |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs)
Tidsramme: First dose date up to 99 days
|
First dose date up to 99 days
|
|
|
Percentage of Participants Experiencing Clinical Laboratory Abnormalities
Tidsramme: First dose date up to 99 days
|
First dose date up to 99 days
|
|
|
Serum PK Parameters MAD: Dose 1 and Dose 5: Cmax of GS-0145
Tidsramme: Up to 99 days
|
Up to 99 days
|
|
|
Serum Pharmacokinetic (PK) Parameter (After Single Ascending Dose (SAD)): AUCinf of GS-0145
Tidsramme: Up to 43 days
|
AUCinf is defined as the area under the concentration versus time curve extrapolated to infinite time, calculated as AUClast + (Clast/λz). |
Up to 43 days
|
|
Serum PK Parameters (SAD): Cmax of GS-0145
Tidsramme: Up to 43 days
|
Cmax is defined as the maximum observed concentration of drug. |
Up to 43 days
|
|
Serum PK Parameters Multiple Ascending Dose (MAD): Dose 1 and Dose 5: AUCtau of GS-0145
Tidsramme: Up to 99 days
|
AUCtau is defined as the area under the concentration versus time curve over the dosing interval. |
Up to 99 days
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Percentages of participants With of Treatment-Emergent Anti-GS-0415 Antibodies
Tidsramme: Up to 99 days
|
Up to 99 days
|
|
Percentages of participants With Virological Rebound (Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) ≥ 50 copies/mL)
Tidsramme: Up to 99 days
|
Up to 99 days
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Gilead Study Director, Gilead Sciences
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- GS-US-531-7345
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .